IN VIVO BIOREACTORS AND METHODS OF MAKING AND USING SAME

• US 20080241250A1
• Filed: 11/08/2007
• Published: 10/02/2008
• Est. Priority Date: 11/08/2006
• Status: Abandoned Application

• Current Assignee: Maastricht University, Vanderbilt University
• Original Assignee: Vanderbilt University
• Inventors: Emans, Pieter J., Shastri, Prasad Venkatram
• Application Number:
  US11/937,068
• Publication Number:
  US 20080241250A1
• Time in Patent Office: Days
• US Class Current: 424/488
• CPC Class Codes: A61L 2430/06 for cartilage reconstruction, e.g. meniscus
• CPC Class Codes: A61L 27/20 Polysaccharides
• CPC Class Codes: A61L 27/3817 Cartilage-forming cells, e.g. pre-chondrocytes
• CPC Class Codes: A61L 27/3852 Cartilage, e.g. meniscus
• CPC Class Codes: A61L 27/52 Hydrogels or hydrocolloids
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders

Abstract

The present invention relates to an in vivo method of promoting the growth of autologous cartilage and bone tissue, including tissue that can be explanted to other locations in the subject.

Claims

1. A method for promoting generation of cartilage tissue, comprising administering in or adjacent to periosteum tissue of a subject a therapeutically effective amount of a biocompatible hydrogel comprising at least one polymer, wherein exogenous cells are substantially absent, wherein non-carbohydrate anti-angiogenic agents and/or growth factors are substantially absent.

2. The method of claim 1, further comprising administering an angiogenic agent in or adjacent to periosteum tissue or to the biocompatible hydrogel, wherein the method promotes generation of bone tissue.

3. The method of claim 1, wherein the polymer comprises one or more saccharide residues having the structure:

4. The method of claim 3, wherein the polymer comprises one or more saccharide residues having the structure:

5. The method of claim 1, wherein the biocompatible hydrogel comprises a diffusion coefficient of oxygen less than 1.5×

10<sup>−

9</sup> m²s<sup>−

1</sup>.

6. The method of claim 1, wherein the biocompatible hydrogel further comprises at least one biocompatible polymer selected from agarose, hyaluronic acid, heparin, a heparin fragment, and mixtures thereof, glycosaminoglycans, glycosylated proteins (proteoglycans), glycosylated non degradable and degradable synthetic polymers, polymers with sugar residues, and self-assemble peptides.

7. The method of claim 1, wherein the biocompatible hydrogel further comprises at least one pharmaceutically active agent.

8. The method of claim 1, wherein the biocompatible hydrogel has a modulus of at least 0.3 megapascals.

9. The method of claim 8, wherein sodium alginate is used to increase modulus of the biocompatible hydrogel.

10. The method of claim 1, wherein the biocompatible hydrogel induces the local production of cytokines, wherein at least one of the cytokines stimulates chondrogenic differentiation of the periosteal cells.

11. The method of claim 1, further comprising the step of creating an artificial space or environment in an organ or cavity of the subject prior to the administration step.

12. The method of claim 11, further comprising the step of harvesting pluripotent or multipotent progenitor cells, chondrocytes, or cartilage from the artificial space or environment after the administration step.

13. The method of claim 12, further comprising the step of re-introducing the harvested progenitor cells, chondrocytes, or cartilage into the subject.

14. A method for promoting generation of cartilage tissue, comprising administering in or adjacent to periosteum tissue of a subject a therapeutically effective amount of a biocompatible hydrogel consisting essentially of agarose and water.

15. The method of claim 14, further comprising administering an angiogenic agent in or adjacent to periosteum tissue or to the biocompatible hydrogel, wherein the method promotes generation of bone tissue.

16. The method of claim 14, further comprising the step of creating an artificial space or environment in an organ or cavity of the subject prior to the administration step.

17. The method of claim 16, further comprising the step of harvesting pluripotent or multipotent progenitor cells, chondrocytes, or cartilage from the artificial space or environment after the administration step.

18. The method of claim 17, further comprising the step of re-introducing the harvested progenitor cells, chondrocytes, or cartilage into the subject.

19. A method for promoting generation of cartilage tissue, comprising the steps of:

(a) creating an artificial space or environment in an organ or cavity of a subject;

(b) administering in or adjacent to periosteum tissue of the subject a therapeutically effective amount of a biocompatible hydrogel, thereby providing a hypoxic environment in the space; and

(c) optionally, harvesting pluripotent or multipotent progenitor cells, chondrocytes, or cartilage from the artificial space or environment after the administration step.

20. A kit for promoting generation of tissue in vivo, comprising a biocompatible hydrogel and two or more of:

(a) a tissue retractor for generating an artificial space at a site in a subject;

(b) an agent to partially degrade connective tissue at the site, thereby freeing cells to promote formation of the space and/or promote migration of cells into the space;

(c) means for warming the hydrogel to a melting temperature; and

(d) means for delivery of the melted gel to the site.

21. The kit of claim 20, wherein the biocompatible hydrogel comprises at least one polymer, wherein exogenous cells are substantially absent, and wherein non-carbohydrate anti-angiogenic agents and/or growth factors are substantially absent.

22. The kit of claim 20, wherein the biocompatible hydrogel consists essentially of agarose and water.

23. The kit of claim 20, comprising;

(a) a biocompatible hydrogel;

(b) a tissue retractor for generating an artificial space at a site in a subject; and

(c) an agent to partially degrade connective tissue at the site, thereby freeing cells to promote formation of the space and/or promote migration of cells into the space.

24. The kit of claim 20, comprising;

(a) a biocompatible hydrogel;

(b) means for warming the hydrogel to a melting temperature; and

(c) means for delivery of the melted gel to the site.

25. The kit of claim 20, wherein the biocompatible hydrogel further comprises at least one pharmaceutically active agent.